Back to News
Market Impact: 0.2
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit
Source: globenewswire.com
Legal & LitigationHealthcare & Biotech
Levi & Korsinsky announced a securities class action against ARS Pharmaceuticals on behalf of investors who bought SPRY shares between March 9, 2026 and June 24, 2026. The notice signals potential legal and reputational risk for the biotech company, although no allegations, damages, or financial impact were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
SPRY-0.80
More News
- Aker BP Q3 profit tops forecast on $870 million writedown reversal
- Kalshi, co-founders hit with criminal charges in US state of Utah
- Judge says Trump's bid to set aside California ballots would ‘wreak havoc’ on democracy
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Utah criminally charges Kalshi with promoting illegal gambling
- FTC and 20 states sue Dollar General, saying it overcharged its poorest customers by millions